Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 2021

View Archived Issues

Exosome-mediated transcellular delivery of SIRT2 modulates ATP homeostasis within axons

PF-06873600 disrupts cell-cycle progression and shows antitumor activity in vivo

UCB describes new IL-17 modulators

New PBP3 ligands identified at Bicycletx

Remix Therapeutics patents RNA splicing modulators

New HIV replication inhibitors discovered at Gilead

Novel malaria vaccine candidate developed using recombinant SAMSP1 mosquito saliva protein

Complement C5 inhibitor RA-101295 protects against hemolytic anemia and kidney injury in baboons

h11B11, a potent hACE2-targeting MAb against SARS-CoV-2 variants

Celularity and Oncternal collaborate to study placental-derived cellular therapies targeting ROR1

Linagliptin ameliorates neurodegeneration in rat model of AD

Mindset reports preclinical data on next-generation psychedelic medicine MSP-4018

ChAdOx1/MVA MAGE vaccine shows synergy with anti-PD-1 cancer therapy

Blade reports preclinical drug-drug interaction data on cudetaxestat for IPF

KLF5 inhibitor AM-80 ameliorates muscular atrophy in mice

Virpax acquires rights to Nanomerics' technology to deliver intranasal cannabidiol product

Trigone Pharma collaborates with 4C Biomed on intravesical immunotherapy for bladder cancer

Mouse models, MOS models, organoids can make personalized predictions

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...